Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032

Overview

The Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market is expected to reach a 11.56 USD Million by 2032 and is projected to grow at a CAGR of 7.89% from 2025 to 2032.

Revenue, 2024 (USD Million)
6.32
Forecast, 2032 (USD Million)
11.56
CAGR, 2024 - 2032
7.89%
Report Coverage
Netherlands

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market 2018-2032 USD Million

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 6.32 USD Million
  • Projected Market Size (2032): 11.56 USD Million
  • CAGR (2025-2032): 7.89%

Key Findings of Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market

  • The Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at 6.32 USD Million in 2024.
  • The Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market is likely to grow at a CAGR of 7.89% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Oncology in Therapeutic Application Segment accounted for the largest share of the market with a revenue of 4.87 USD Million
  • The fastest growing segment Small Molecule Ligands in Vector Type Segment grew Fastest with a CAGR of 8.47% during the forecast period from 2024 to 2032.

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Segmentation & Scope
Isotope
  • Alpha Emitters
  • Beta Emitters
Vector Type
  • Others
  • Monoclonal Antibodies
  • Peptides
  • Small Molecule Ligands
End User
  • Research Institutes
  • Radiopharmacies
  • Hospitals
Therapeutic Application
  • Others
  • Oncology
Sources
  • Others
  • Generator-Produced Isotopes
  • Reactor-Produced Isotopes

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Data Coverage Insights

Study Period 2024-2032
Base Year 2024
Unit Revenue in USD Million
Market Value in 2024 6.32 USD Million
Market Value in 2032 11.56 USD Million
CAGR (2025-2032) 7.89%
Historic Data 2016-2023
Market Segments Covered Isotope,Vector Type,End User,Therapeutic Application,Sources

Regional Insights:

  • Leading Market (2024-2032): Netherlands, leading in terms of revenue 6.32 USD Million in 2024
    • Key Country: Netherlands, leading in terms of revenue with value of 6.32 USD Million in 2024.

Segments and Scope

  • Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Isotope
    • Beta Emitters is the largest segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.63 USD Million in the year 2024.
    • Beta Emitters is the Fastest growing segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.05 % in forecast period 2025-2032.
  • Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Vector Type
    • Small Molecule Ligands is the largest segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.29 USD Million in the year 2024.
    • Small Molecule Ligands is the Fastest growing segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.47 % in forecast period 2025-2032.
  • Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By End User
    • Hospitals is the largest segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.61 USD Million in the year 2024.
    • Hospitals is the Fastest growing segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.02 % in forecast period 2025-2032.
  • Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Therapeutic Application
    • Oncology is the largest segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 4.87 USD Million in the year 2024.
    • Oncology is the Fastest growing segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.22 % in forecast period 2025-2032.
  • Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Sources
    • Reactor-Produced Isotopes is the largest segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.93 USD Million in the year 2024.
    • Reactor-Produced Isotopes is the Fastest growing segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.02 % in forecast period 2025-2032.

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Share Analysis

 
Company Name Company Share Analysis
Novartis AG
Eckert & Ziegler
ITM Isotope Technologies Munich SE
SHINE Technologies, LLC
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Share Analysis

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Geographical Sales Distribution, 2018-2032 USD Million

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Geographical Sales Distribution, 2018-2032 USD Million

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling
Frequently Asked Questions
The Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market is segmented based on Segmentation Isotope,Vector Type,End User,Therapeutic Application,Sources.
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at USD 6.32(Revenue in USD Million) in 2024.
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market is projected to grow at a CAGR of 7.89% during the forecast period of 2024 to 2032.
The Oncology segment is expected to dominate the Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market, holding a largest market share of 4.87 USD Million in 2024

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Segmentation & Scope
Isotope
  • Alpha Emitters
  • Beta Emitters
Vector Type
  • Others
  • Monoclonal Antibodies
  • Peptides
  • Small Molecule Ligands
End User
  • Research Institutes
  • Radiopharmacies
  • Hospitals
Therapeutic Application
  • Others
  • Oncology
Sources
  • Others
  • Generator-Produced Isotopes
  • Reactor-Produced Isotopes
Frequently Asked Questions
The Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market is segmented based on Segmentation Isotope,Vector Type,End User,Therapeutic Application,Sources.
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at USD 6.32(Revenue in USD Million) in 2024.
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market is projected to grow at a CAGR of 7.89% during the forecast period of 2024 to 2032.
The estimated market value of the Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market for final year is USD 11.56 (USD Million).

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling

Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling
Frequently Asked Questions
The Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market is segmented based on Segmentation Isotope,Vector Type,End User,Therapeutic Application,Sources.
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at USD 6.32(Revenue in USD Million) in 2024.
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market is projected to grow at a CAGR of 7.89% during the forecast period of 2024 to 2032.
The estimated market value of the Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market for final year is USD 11.56 (USD Million).